DDInter1054 DDInter1180
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the blood-brain barrier[Label,A177781]. Once past the blood-brain barrier, levodopa is metabolized to dopamine and supplements the low endogenous levels of dopamine to treat symptoms of Parkinson's[Label]. The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Levodopa {u} (Compound) resembles {v} (Compound) Levonordefrin
Levodopa {u} (Compound) resembles {v} (Compound) Isoetharine
Levodopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Levodopa {u} (Compound) binds {v} (Gene) DRD1
Levodopa {u} (Compound) upregulates {v} (Gene) CADM1
Levodopa {u} (Compound) palliates {v} (Disease) restless legs syndrome
Levodopa {u} (Compound) is included by {v} (Pharmacologic Class) DOPA Decarboxylase Inhibitors
Levodopa {u} (Compound) downregulates {v} (Gene) P4HTM
Levodopa {u} (Compound) causes {v} (Side Effect) Hyperhidrosis
Levodopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aluminum hydroxide
Levodopa (Compound) resembles Levonordefrin (Compound)
Levodopa (Compound) resembles Isoetharine (Compound)
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Levodopa (Compound) binds DRD1 (Gene)
Levodopa (Compound) upregulates CADM1 (Gene)
Levodopa (Compound) palliates restless legs syndrome (Disease)
Levodopa (Compound) is included by DOPA Decarboxylase Inhibitors (Pharmacologic Class)
Levodopa (Compound) downregulates P4HTM (Gene)
Levodopa (Compound) causes Hyperhidrosis (Side Effect)
Levodopa may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide